NASDAQ:SYNH - Syneos Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $98.78
  • Forecasted Upside: 38.02 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$71.57
▼ -0.11 (-0.15%)

This chart shows the closing price for SYNH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Syneos Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYNH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYNH

Analyst Price Target is $98.78
▲ +38.02% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Syneos Health in the last 3 months. The average price target is $98.78, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 38.02% upside from the last price of $71.57.

This chart shows the closing price for SYNH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Syneos Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/9/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2022GuggenheimInitiated CoverageBuy$81.00Medium
5/20/2022MizuhoReiterated RatingBuy$94.00Low
4/25/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$101.00 ➝ $75.00High
4/11/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$102.00Medium
3/7/2022MizuhoLower Price TargetBuy$109.00 ➝ $94.00High
1/27/2022BarclaysLower Price TargetOverweight$115.00 ➝ $105.00Low
12/15/2021CitigroupDowngradeBuy ➝ Neutral$115.00 ➝ $105.00High
11/4/2021Robert W. BairdBoost Price TargetPositive ➝ Outperform$115.00 ➝ $122.00High
11/4/2021BarclaysUpgradeEqual Weight ➝ Overweight$98.00 ➝ $115.00High
11/4/2021KeyCorpBoost Price TargetOverweight$100.00 ➝ $105.00High
8/5/2021Credit Suisse GroupBoost Price TargetOutperform$96.00 ➝ $100.00High
7/13/2021BarclaysBoost Price TargetEqual Weight$90.00 ➝ $102.00Low
4/30/2021MizuhoBoost Price TargetBuy$82.00 ➝ $90.00Medium
3/8/2021BarclaysInitiated CoverageEqual Weight$84.00N/A
3/8/2021KeyCorpBoost Price TargetOverweight$76.00 ➝ $90.00Medium
3/2/2021BarclaysInitiated CoverageEqual Weight$84.00Medium
2/22/2021MizuhoBoost Price TargetBuy$72.00 ➝ $87.00Medium
2/19/2021CitigroupBoost Price Target$80.00 ➝ $85.00Low
12/9/2020JPMorgan Chase & Co.Boost Price TargetOverweight$80.00 ➝ $85.00Low
12/9/2020Smith Barney CitigroupBoost Price Target$75.00 ➝ $80.00Low
12/9/2020MizuhoBoost Price TargetPositive ➝ Buy$65.00 ➝ $72.00Low
12/7/2020Credit Suisse GroupBoost Price TargetOutperform$72.00 ➝ $75.00Medium
10/6/2020MizuhoUpgradeNeutral ➝ Buy$63.00 ➝ $65.00Low
10/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$69.00 ➝ $75.00High
8/12/2020Truist FinancialBoost Price TargetBuy$74.00 ➝ $80.00Medium
8/7/2020CitigroupBoost Price TargetBuy$70.00 ➝ $75.00Low
8/7/2020MizuhoBoost Price TargetNeutral$50.00 ➝ $63.00Low
7/16/2020SunTrust BanksBoost Price TargetBuy$66.00 ➝ $74.00Low
5/1/2020SunTrust BanksBoost Price TargetBuy$56.00 ➝ $66.00Medium
4/30/2020CfraBoost Price TargetBuy$55.00 ➝ $61.00Medium
4/28/2020UBS GroupLower Price TargetNeutral$74.00 ➝ $58.00High
4/9/2020CitigroupLower Price TargetBuy$85.00 ➝ $65.00High
4/3/2020MizuhoLower Price TargetNeutral$56.00 ➝ $42.00Medium
4/2/2020Credit Suisse GroupLower Price TargetOutperform$72.00 ➝ $62.00High
3/30/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$79.00 ➝ $45.00High
3/26/2020BarclaysLower Price TargetEqual Weight$67.00 ➝ $61.00Medium
3/23/2020Jefferies Financial GroupLower Price TargetBuy$80.00 ➝ $52.00Medium
3/17/2020SunTrust BanksLower Price TargetBuy$80.00 ➝ $58.00Low
2/23/2020BarclaysReiterated RatingHold$67.00High
2/21/2020Credit Suisse GroupBoost Price TargetOutperform$68.00 ➝ $72.00Low
2/21/2020Robert W. BairdBoost Price TargetOutperform$74.00 ➝ $82.00Low
2/21/2020UBS GroupBoost Price TargetNeutral$62.00 ➝ $74.00Low
2/21/2020MizuhoBoost Price TargetNeutral$52.00 ➝ $67.00Low
1/21/2020Credit Suisse GroupReiterated RatingBuy$68.00Low
1/16/2020Robert W. BairdBoost Price TargetOutperform$62.00 ➝ $74.00Medium
1/16/2020KeyCorpBoost Price TargetOverweight$65.00 ➝ $71.00Medium
1/6/2020CitigroupInitiated CoverageBuy$75.00Low
9/23/2019Jefferies Financial GroupBoost Price TargetBuy$62.00 ➝ $65.00Low
9/3/2019KeyCorpBoost Price TargetOverweight$63.00 ➝ $65.00Low
8/29/2019UBS GroupBoost Price TargetNeutral$53.50 ➝ $57.00Low
8/23/2019Credit Suisse GroupBoost Price TargetOutperform$56.00 ➝ $58.00High
8/8/2019KeyCorpBoost Price TargetOverweight$59.00 ➝ $63.00Low
8/7/2019SunTrust BanksBoost Price TargetBuy$68.00Low
4/17/2019BarclaysReiterated RatingHold$48.00High
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformMedium
3/19/2019UBS GroupDowngradeBuy ➝ Neutral$55.00Low
3/19/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$49.00 ➝ $51.00Low
3/19/2019William BlairReiterated RatingOutperformMedium
1/8/2019Robert W. BairdSet Price TargetBuy$60.00Low
1/3/2019BarclaysLower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $45.00Low
12/19/2018SunTrust BanksLower Price TargetBuy$55.00Low
10/19/2018William BlairUpgradeMarket Perform ➝ OutperformLow
10/9/2018UBS GroupInitiated CoverageBuy ➝ Buy$60.00Low
10/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$58.00High
8/10/2018KeyCorpBoost Price TargetOverweight ➝ Overweight$54.00 ➝ $59.00Low
8/6/2018MizuhoReiterated RatingHold$51.00High
8/3/2018SunTrust BanksReiterated RatingBuy$60.00Low
8/3/2018BarclaysReiterated RatingEqual Weight ➝ Hold$43.00 ➝ $51.00Medium
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$50.00Low
3/1/2018BarclaysReiterated RatingEqual Weight ➝ Equal Weight$40.00 ➝ $43.00Low
3/1/2018SunTrust BanksBoost Price TargetBuy$55.00Low
2/26/2018KeyCorpReiterated RatingOverweight ➝ Overweight$50.00 ➝ $46.00Low
2/23/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
2/22/2018Robert W. BairdSet Price TargetBuy$50.00High
1/4/2018Credit Suisse GroupReiterated RatingBuy$52.00Medium
1/4/2018KeyCorpReiterated RatingBuy$50.00Medium
12/11/2017BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$40.00High
12/1/2017SunTrust BanksLower Price TargetBuy$50.00Medium
12/1/2017MizuhoSet Price TargetNeutral ➝ Neutral$57.00 ➝ $41.00Medium
11/16/2017Robert W. BairdSet Price TargetBuy$46.00N/A
11/14/2017Credit Suisse GroupLower Price TargetOutperform$68.00 ➝ $54.00N/A
11/13/2017KeyCorpReiterated RatingOverweight ➝ Market Perform$68.00 ➝ $46.00N/A
11/10/2017Jefferies Financial GroupReiterated RatingBuy$55.00N/A
11/10/2017Robert W. BairdDowngradeOutperform$67.00 ➝ $46.00N/A
10/11/2017Credit Suisse GroupInitiated CoverageOutperform$68.00N/A
10/9/2017Jefferies Financial GroupUpgradeHold ➝ Buy$62.50 ➝ $69.00N/A
10/9/2017Robert W. BairdReiterated RatingBuy$67.00N/A
9/21/2017MizuhoInitiated CoverageNeutral$57.00Low
8/7/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$65.00Low
7/30/2017Jefferies Financial GroupReiterated RatingHold$62.50Low
(Data available from 7/3/2017 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/4/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/3/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/4/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/4/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/3/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/3/2022

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Syneos Health logo
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $71.57
Low: $70.11
High: $72.26

50 Day Range

MA: $70.52
Low: $63.06
High: $75.71

52 Week Range

Now: $71.57
Low: $62.28
High: $104.18

Volume

420,301 shs

Average Volume

574,242 shs

Market Capitalization

$7.34 billion

P/E Ratio

30.98

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Syneos Health?

The following equities research analysts have issued reports on Syneos Health in the last year: Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group Inc., KeyCorp, Mizuho, Robert W. Baird, StockNews.com, and TheStreet.
View the latest analyst ratings for SYNH.

What is the current price target for Syneos Health?

0 Wall Street analysts have set twelve-month price targets for Syneos Health in the last year. Their average twelve-month price target is $98.78, suggesting a possible upside of 38.0%.
View the latest price targets for SYNH.

What is the current consensus analyst rating for Syneos Health?

Syneos Health currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYNH will outperform the market and that investors should add to their positions of Syneos Health.
View the latest ratings for SYNH.

How do I contact Syneos Health's investor relations team?

Syneos Health's physical mailing address is 1030 Sync Street, Morrisville NC, 27560. The company's listed phone number is (919) 876-9300 and its investor relations email address is [email protected] The official website for Syneos Health is www.syneoshealth.com. Learn More about contacing Syneos Health investor relations.